阿霉素在纳米递送系统中联合用药的研究进展  

Research progress on the co-administration of doxorubicin in novel delivery systems

作　　者：李江 史雄喜 刘佳慧 陈建明[1] 武鑫 LI Jiang;SHI Xiongxi;LIU Jiahui;CHEN Jianming;WU Xin(School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China;Shanghai Weier Laboratory,Shanghai 201712,China)

机构地区：[1]福建中医药大学药学院,福建福州350122 [2]上海维洱实验室,上海201712

出　　处：《药学研究》2023年第9期703-707,713,共6页Journal of Pharmaceutical Research

基　　金：国家自然科学基金(No.81772749);福建中医药大学高层次人才科研启动资金项目(No.X2019006-人才);上海青浦区产学研合作发展资金项目资助(No.青产学研2021-7)。

摘　　要：阿霉素是一种常见的抗肿瘤药物,在临床上用于治疗乳腺癌、淋巴癌、卵巢癌等。但由于心脏毒性抑制、肿瘤的多药耐药性等因素,阿霉素通常与其他药物联合使用以解决以上问题。随着纳米技术的发展,许多纳米载体被开发用于共递送两种药物,以提高药物疗效、降低毒副作用、克服肿瘤的多药耐药性等。故本文对近年来阿霉素联合用药在纳米递送系统中的研究进行综述,以期为阿霉素联合用药的研究提供参考。Doxorubicin is a common antitumor drug used in clinical practice for the treatment of breast cancer,lymphoma,ovarian cancer,etc.Due to factors such as cardiotoxicity inhibition and multidrug resistance,doxorubicin is usually used in combination with other drugs to solve the above problems.With the development of nanotechnology,many nanocarriers have been developed for the co-delivery of two drugs to improve drug efficacy,reduce toxic side effects,overcome multidrug resistance of tumors,etc.Therefore,this paper reviews the recent studies of doxorubicin co-administration in nano delivery systems in order to provide a reference for the research of doxorubicin co-administration.

关 键 词：阿霉素 联合用药 药物递送系统 纳米制剂 

分 类 号：R979.1[医药卫生—药品]